media – Page 35 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

【EXPERT Q&A】What is the need for a home monitor?

Drugdu.com expert’s response: The necessity of home monitoring devices is mainly reflected in the following aspects: Ⅰ. Enhancing Monitoring Efficiency and Accuracy Home monitoring devices can accurately monitor vital signs, including ECG, blood pressure, blood oxygen levels, body temperature, respiration, and other key indicators. These devices utilize advanced technology to quickly provide reliable data, allowing users to have a clear understanding of their health status. Compared to traditional self-monitoring methods, home monitoring devices are more precise and efficient, aiding in the timely detection of potential health issues. Ⅱ. Meeting the Need for In-home Monitoring With the intensifying trend of population aging and the rising incidence of chronic diseases, an increasing number of elderly individuals require long-term health monitoring. The portability and ease of use of home monitoring devices make in-home monitoring feasible. Elderly individuals can monitor their health at any time in their homes, eliminating the need for frequent visits ...
- Source: drugdu
- 72
- November 4, 2024
single-cell transcriptomics and proteomic analysis

Parkinson’s disease is a common neurodegenerative disorder characterized by movement disorders, autonomic dysfunction, and sleep cognitive problems, affecting nearly 6 million people worldwide. Its neuropathological features include the loss of dopaminergic neurons and the aggregation of alpha synuclein within cells. Although neuroinflammation involving glial cells and immune cells is believed to be related to the pathogenesis of Parkinson’s disease, further research is needed to determine whether these pathways are associated with sporadic diseases. In addition, the relative contributions of neurons and glial cells in Parkinson’s pathology are still unclear. Although single-cell technology, including multi omics analysis, is gradually becoming a popular method for studying neurodegenerative diseases, these tools are only now beginning to be applied in Parkinson’s disease research, especially utilizing human brain tissue. On October 30, 2024, the Zhang Le research group at Yale University published a research paper titled “Single cell transcriptomic and proteomic analysis of Parkinson’s disease ...
- Source: drugdu
- 111
- November 4, 2024
Nat Commun | Professor Ouyang Songying’s team reveals the activation mechanism of Sir2 HerA system in pathogenic bacteria’s phage immunity

In the long-term and intense survival competition between bacteria, archaea, and bacteriophages, they have evolved various complex antiviral systems to resist the invasion of bacteriophages. The latest research reveals that approximately 7% of sequenced bacterial genomes have at least one defense system, among which the depletion of nicotinamide adenine dinucleotide (NAD+) is a common strategy to combat phage induced miscarriage infections. The hydrolysis of NAD+is mainly performed by proteins containing TIR and Sir2 domains. Recently, Professor Ouyang Songying’s team from the School of Life Sciences at Fujian Normal University collaborated to publish a paper titled “Mechanical Basis for the Allosteric Activation of NADase Activity in the Sir2 HerA Antiphage Defense System” online in Nature Communications. This study uses bioinformatics, structural biology, and experimental techniques such as biochemistry to reveal the molecular mechanism of how the Sir2 HerA system is activated and exerts its anti phage function in pathogen immunity.The Sir2 ...
- Source: drugdu
- 66
- November 4, 2024
16 billion yuan! Novartis “runs” to enter the market

Recently, the molecular glue star company Monte Rosa Therapeutics announced that it has reached a global exclusive development and commercialization license agreement with Novartis to advance the development of molecular glue protein degraders targeting VAV1, including the research therapy MRT-6160. Under the terms of the agreement, Novartis agreed to pay Monte Rosa an advance payment of US$150 million. In addition, Monte Rosa is eligible to receive up to US$2.1 billion in development, regulatory and sales milestone payments (US$2.25 billion is approximately RMB 16 billion). Monte Rosa Therapeutics is headquartered in Boston, USA. The company was founded in 2018 and is a biotechnology company focusing on the development of molecular glue drugs. Its core technology platform is the QuEEN platform, which is mainly dedicated to the discovery and development of molecular glue drugs. Under the terms of the agreement, Monte Rosa will continue to be responsible for completing the ongoing Phase ...
- Source: drugdu
- 55
- November 4, 2024
Domestic PD-L1 was approved in the UK for the first time

CStone Pharmaceuticals announced today (October 31) that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab combined with platinum-containing chemotherapy for patients without EGFR sensitive mutations, or without ALK, ROS1, First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with RET genomic tumor variants. This is the second marketing authorization application approval for sugalimab in overseas markets, following the approval by the European Commission. The approval was mainly based on the results of a multi-center, randomized, double-blind Phase III clinical study – GEMSTONE-302. Sugemalimab combined with chemotherapy can significantly extend the progression-free survival and overall survival of patients with newly treated metastatic NSCLC compared with placebo combined with chemotherapy. The research data has been published in The Lancet Oncology and Nature Cancer, and has been presented in oral and poster presentations at many international academic conferences. CStone Pharmaceuticals has reached a strategic cooperation with ...
- Source: drugdu
- 60
- November 4, 2024
Aimei Vaccine’s 13-Valent Conjugate Pneumococcal Vaccine Obtains Production License and Market Registration Submitted

On November 1, Aimei Vaccine announced that it has submitted a drug market registration application for its self-developed 13-valent conjugate pneumococcal vaccine to the National Medical Products Administration. The results from a completed Phase III clinical study show that Aimei’s 13-valent conjugate pneumococcal vaccine has demonstrated good immunogenicity and safety, meeting the clinical preset objectives. Aimei’s wholly-owned subsidiary, Aimei Biotechnology Co., Ltd., has obtained the corresponding drug production license for this product. The 13-valent conjugate pneumococcal vaccine has been referred to as the “king of global vaccines” and has been the world’s top-selling vaccine for ten consecutive years. Pfizer’s 13-valent conjugate pneumococcal vaccine (Prevnar 13®) is the best-selling vaccine globally and has frequently ranked among the top ten best-selling drugs worldwide. According to Pfizer’s 2023 annual report, global sales of Pfizer’s pneumococcal conjugate vaccine were approximately $6.44 billion in 2023. Over the years, the global sales of the 13-valent conjugate ...
- Source: drugdu
- 53
- November 4, 2024
Lizhong Group Reports Net Profit of 1.673 Billion Yuan in First Three Quarters, Revenue Declines for Five Consecutive Quarters

China Net Finance, November 1 – In the context of an expanding centralized procurement and a cool market for innovative drugs, Lizhong Group has still managed to maintain profit growth. The third-quarter report shows that the company achieved a net profit of 500 million yuan in a single quarter, a year-on-year increase of 7.45%. For the first three quarters, the cumulative net profit attributable to shareholders reached 1.673 billion yuan, which represents a year-on-year growth of 4.44%. The net profit after eliminating non-recurring gains and losses was approximately 1.631 billion yuan, up by 3.51%. In contrast to profit growth, Lizhong Group’s revenue has shown a downward trend. In the first three quarters, the company reported approximately 9.082 billion yuan in operating revenue, a year-on-year decline of 5.94%. From a quarterly perspective, Lizhong Group’s revenue has been declining for five consecutive quarters, with the first three quarters of this year reporting ...
- Source: drugdu
- 50
- November 4, 2024
Is the turning point of “Cosmic Pharmaceutical Factory” coming?

In 2022, Pfizer’s annual revenue exceeded $100 billion, making it the world’s largest pharmaceutical company in terms of revenue. However, as the COVID-19 pandemic quickly receded, revenue fell by 41% in 2023, and revenue ranking also dropped from first to fourth. Recently, the well-known radical investment institution Starboard Value invested $1 billion in Pfizer. What changes will this bring to this pharmaceutical giant? In 1849, Charles Pfizer and Charles Erhart founded Pfizer in New York, initially focusing on the production of chemical products. During World War II, Pfizer successfully mass-produced penicillin and launched oxytetracycline, officially entering the pharmaceutical industry. Since then, Pfizer has continued to expand through research and development and mergers and acquisitions, launched blockbuster drugs such as Norvasc and Viagra, and gradually became a leading global pharmaceutical company. Since the 21st century, Pfizer has topped the list of the top 50 pharmaceutical companies in the world (Pharm Exec ...
- Source: drugdu
- 109
- November 2, 2024
It is better to look at the long-term situation

October is coming to an end, and the third quarter “exam” of the innovative drug industry will also come to an end. From the surface, although the entire industry is still turbulent, new drug research and development is crowded with “involution”, commercialization challenges are numerous, and the capital winter is still spreading, but from the performance point of view, the situation does not seem to be as bad as imagined. On the one hand, as the product strength and commercialization capabilities of leading innovative pharmaceutical companies are constantly confirmed, their revenue continues to grow at a high rate and their profitability is enhanced; on the other hand, more and more pharmaceutical companies have also achieved phased results in cost control in reducing costs and increasing efficiency. The resonance of the two major factors has further expanded the “loss reduction” camp. Various signs indicate that in the cold winter after the ...
- Source: drugdu
- 76
- November 2, 2024
Domestic TCE polyclonal antibodies are “surging”

MNCs are hunting for domestic molecules and have already involved the field of TCE polyclonal antibodies. On October 29, GlaxoSmithKline announced the acquisition of Enmu Bio’s CD19 and CD20 targeted T cell engager CMG1A46, including a $300 million advance payment and $550 million in potential milestone payments. Not long ago in August, Merck also bought Tongrun Bio’s CD3xCD19 bispecific antibody CN201 with a down payment of $700 million and a milestone payment of $600 million. The direction of the giants is also relatively consistent: betting on the autoimmune market. At present, the core “battlefield” of TCE polyclonal antibodies is tumors. TCE polyclonal antibodies are relatively special. One end (or two ends) is connected to TAA (tumor-associated antigen) to locate tumor cells, and the other end is connected to the CD3 epitope of T cells to activate T cells and exert the tumor-killing effect of T cells. In the field of ...
- Source: drugdu
- 69
- November 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.